Cargando…

Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial

BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarito, Mauro, Sanz-Sanchez, Jorge, Piccolo, Raffaele, Condello, Francesco, Liccardo, Gaetano, Maurina, Matteo, Avvedimento, Marisa, Regazzoli, Damiano, Pagnotta, Paolo, Garcia-Garcia, Hector M., Mehran, Roxana, Federici, Massimo, Condorelli, Gianluigi, Diez Gil, Jose Luis, Reimers, Bernhard, Ferrante, Giuseppe, Stefanini, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902064/
https://www.ncbi.nlm.nih.gov/pubmed/36747244
http://dx.doi.org/10.1186/s12933-023-01744-4
_version_ 1784883165571055616
author Chiarito, Mauro
Sanz-Sanchez, Jorge
Piccolo, Raffaele
Condello, Francesco
Liccardo, Gaetano
Maurina, Matteo
Avvedimento, Marisa
Regazzoli, Damiano
Pagnotta, Paolo
Garcia-Garcia, Hector M.
Mehran, Roxana
Federici, Massimo
Condorelli, Gianluigi
Diez Gil, Jose Luis
Reimers, Bernhard
Ferrante, Giuseppe
Stefanini, Giulio
author_facet Chiarito, Mauro
Sanz-Sanchez, Jorge
Piccolo, Raffaele
Condello, Francesco
Liccardo, Gaetano
Maurina, Matteo
Avvedimento, Marisa
Regazzoli, Damiano
Pagnotta, Paolo
Garcia-Garcia, Hector M.
Mehran, Roxana
Federici, Massimo
Condorelli, Gianluigi
Diez Gil, Jose Luis
Reimers, Bernhard
Ferrante, Giuseppe
Stefanini, Giulio
author_sort Chiarito, Mauro
collection PubMed
description BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels. METHODS: In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality. RESULTS: 142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3–2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3–2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR − 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43–150), no patients required hemodialysis and 2 patients died due to non-cardiac causes. CONCLUSIONS: In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function. Trial registration: The study was registered at Clinicaltrials.gov (NCT04766008). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01744-4.
format Online
Article
Text
id pubmed-9902064
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99020642023-02-07 Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial Chiarito, Mauro Sanz-Sanchez, Jorge Piccolo, Raffaele Condello, Francesco Liccardo, Gaetano Maurina, Matteo Avvedimento, Marisa Regazzoli, Damiano Pagnotta, Paolo Garcia-Garcia, Hector M. Mehran, Roxana Federici, Massimo Condorelli, Gianluigi Diez Gil, Jose Luis Reimers, Bernhard Ferrante, Giuseppe Stefanini, Giulio Cardiovasc Diabetol Research BACKGROUND: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels. METHODS: In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality. RESULTS: 142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3–2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3–2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR − 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43–150), no patients required hemodialysis and 2 patients died due to non-cardiac causes. CONCLUSIONS: In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function. Trial registration: The study was registered at Clinicaltrials.gov (NCT04766008). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01744-4. BioMed Central 2023-02-06 /pmc/articles/PMC9902064/ /pubmed/36747244 http://dx.doi.org/10.1186/s12933-023-01744-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chiarito, Mauro
Sanz-Sanchez, Jorge
Piccolo, Raffaele
Condello, Francesco
Liccardo, Gaetano
Maurina, Matteo
Avvedimento, Marisa
Regazzoli, Damiano
Pagnotta, Paolo
Garcia-Garcia, Hector M.
Mehran, Roxana
Federici, Massimo
Condorelli, Gianluigi
Diez Gil, Jose Luis
Reimers, Bernhard
Ferrante, Giuseppe
Stefanini, Giulio
Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title_full Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title_fullStr Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title_full_unstemmed Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title_short Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
title_sort safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the no-stop single arm trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902064/
https://www.ncbi.nlm.nih.gov/pubmed/36747244
http://dx.doi.org/10.1186/s12933-023-01744-4
work_keys_str_mv AT chiaritomauro safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT sanzsanchezjorge safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT piccoloraffaele safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT condellofrancesco safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT liccardogaetano safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT maurinamatteo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT avvedimentomarisa safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT regazzolidamiano safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT pagnottapaolo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT garciagarciahectorm safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT mehranroxana safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT federicimassimo safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT condorelligianluigi safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT diezgiljoseluis safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT reimersbernhard safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT ferrantegiuseppe safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial
AT stefaninigiulio safetyofmetformincontinuationindiabeticpatientsundergoinginvasivecoronaryangiographythenostopsinglearmtrial